Phospholipid transfer protein in lipid metabolism

Current Opinion in Lipidology

Volumn 11, Issue 3, 2000, Pages 285-289

  Huuskonen, Jarkko ^a   Ehnholm, Christian ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL;

HUMAN; KNOCKOUT MOUSE; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SITE DIRECTED MUTAGENESIS;

ANIMALS; ARTERIOSCLEROSIS; CARRIER PROTEINS; HUMANS; LIPOPROTEINS, HDL; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; MUTAGENESIS, SITE-DIRECTED; PHOSPHOLIPID TRANSFER PROTEINS;

EID: 0034128334     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200006000-00009     Document Type: Review

References (41)

1. 1 Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res 1968; 9:155-167.
2. 2 Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry 1988; 27:25-29.
3. 3 Day JR, Albers JJ, Lofton-Day CE, Gilbert TL, Ching AF, Grant FJ, et al. Complete cDNA encoding human phospholipid transfer protein from human endothelial cells. J Biol Chem 1994; 269:9388-9391.
4. 4 Rao R, Albers JJ, Wolfbauer G, Pownall HJ. Molecular and macromolecular specificity of human plasma phospholipid transfer protein. Biochemistry 1997; 36:3645-3653.
5. 5 Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 1993; 268:4032-4036.
6. 6 Tu AY, Nishida HI, Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J Biol Chem 1993; 268:23098-23105.
7. 7 Jiang X, Francone OL, Bruce C, Milne R, Mar J, Walsh A, Breslow JL, et al. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 1996; 98:2373-2380.
8. 8 Albers JJ, Tu AY, Paigen B, Chen H, Cheung MC, Marcovina SM. Transgenic mice expressing human phospholipid transfer protein have increased HDL/non-HDL cholesterol ratio. Int J Clin Lab Res 1996; 26:262-267.
9. 9 Foger B, Santamarina-Fojo S, Shamburek RD, Parrot CL, Talley GD, Brewer Jr HB. Plasma phospholipid transfer protein. Adenovirus-mediated overexpression in mice leads to decreased plasma high density lipoprotein (HDL) and enhanced hepatic uptake of phospholipids and cholesteryl esters from HDL. J Biol Chem 1997; 272:27393-27400.
10. 10 Ehnholm S, van Dijk KW, van't Hof B, van der Zee A, Olkkonen VM, Jauhiainen M, et al. Adenovirus mediated overexpression of human phospholipid transfer protein alters plasma HDL levels in mice. J Lipid Res 1998; 39:1248-1253.
11. 11 Huuskonen J, Wohlfahrt G, Jauhiainen M, Ehnholm C, Teleman O, Olkkonen VM. Structure and phospholipid transfer activity of human PLTP: analysis by molecular modeling and site-directed mutagenesis. J Lipid Res 1999; 40:1123-1130. Site-directed mutagenesis, based on the presented molecular model of PLTP, is used to demonstrate the functional importance of lipid-binding pockets, which are conserved in all the members of the lipopolysaccharide-binding/lipid transfer protein family.
12. 12 Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 1997; 276:1861-1864.
13. 13 Huuskonen J, Jauhiainen M, Ehnholm C, Olkkonen VM. Biosynthesis and secretion of human plasma phospholipid transfer protein. J Lipid Res 1998; 39:2021-2030.
14. 14 Qu SJ, Fan HZ, Kilinc C, Pownall HJ. Role of cysteine residues in human plasma phospholipid transfer protein. J Protein Chem 1999; 18:193-198. This study uses site-directed mutagenesis to demonstrate the presence of a disulphide bridge in PLTP molecule.
15. 15 Horwitz AH, Leigh SD, Abrahamson S, Gazzano-Santoro H, Liu PS, Williams RE, et al. Expression and characterization of cysteine-modified variants of an amino-terminal fragment of bactericidal/permeability-increasing protein. Protein Expr Purif 1996; 8:28-40.
16. 16 Capodici C, Weiss J. Both N-and C-terminal regions of the bioactive N-terminal fragment of the neutrophil granule bactericidal/permeability-increasing protein are required for stability and function. J Immunol 1996; 156:4789-4796.
17. 17 Tall AR, Krumholz S, Olivecrona T, Deckelbaum PJ. Plasma phospholipid transfer protein enhances transfer and exchange of phospholipids between very low density lipoproteins and high density lipoproteins during lipolysis. J Lipid Res 1985; 26:842-851.
18. 18 Jiang XC, Bruce C, Mar J, Lin M, Ji Y, Francone OL, Tall AR. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999; 103:907-914. The PLTP knock-out mouse model is used to demostrate the importance of PLTP in phospholipid transfer reaction in in-vivo conditions. Furthermore, solid evidence for the involvement of PLTP in HDL metabolism is presented.
19. 19 Nishida HI, Nishida T. Phospholipid transfer protein mediates transfer of not only phosphatidylcholine but also cholesterol from phosphatidylcholine-cholesterol vesicles to high density lipoproteins. J Biol Chem 1997; 272:6959-6964.
20. 20 Qin S, Kawano K, Bruce C, Lin M, Bisgaier C, Tall AR, Jiang X-C. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. J Lipid Res 2000; 41:269-276. The follow-up study of the PLTP knock-out mouse model provides evidence for increased catabolism of HDL particles as an explanation for the reduced HDL-cholesterol levels in these mice.
21. 21 Wolfbauer G, Albers JJ, Oram JF. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim Biophys Acta 1999; 1439:65-76. This study demonstrates that PLTP is capable of influencing the HDL-mediated cholesterol efflux process in cholesterol-loaded skin fibroblasts.
22. 22 Yokoyama S. Apolipoprotein-mediated cellular cholesterol efflux. Biochim Biophys Acta 1998; 1392:1-15.
23. 23 van Haperen R, van Tol A, Vermeulen P, Jauhiainen M, van Gent T, van den Berg P, et al. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000; 20. The third transgenic PLTP mouse model demonstrates the increased potential of plasma from transgenic animals to generate preβ-HDL and to prevent accumulation of intracellular cholesterol in macrophages compared with plasma from wild-type animals.
24. 24 Steinberg D, Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 1997; 95:1062-1071.
25. 24 Kostner GM, Oettl K, Jauhiainen M, Ehnholm C, Esterbauer H, Dieplinger H. Human plasma phospholipid transfer protein accelerates exchange/transfer of alpha-tocopherol between lipoproteins and cells. Biochem J 1995; 305(Pt 2):659-667.
26. 26 Desrumaux C, Deckert V, Athias A, Masson D, Lizard G, Palleau V, et al. Plasma phospholipid transfer protein prevents vascular endothelium dysfunction by delivering alpha-tocopherol to endothelial cells. FASEB J 1999; 13:883-892. The potential role of PLTP in atheroprotection is suggested, based on PLTP-mediated α-tocopherol transfer preventing the LDL oxidation and endothelial dysfunction.
27. 27 Riemens SC, Van Tol A, Stulp BK, Dullaart RP. Influence of insulin sensitivity and the TaqlB cholesteryl ester transfer protein gene polymorphism on plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities and their response to hyperinsulinemia in non-diabetic men. J Lipid Res 1999; 40:1467-1474.
28. 28 Lagrost L, Athias A, Lemort N, Richard JL, Desrumaux C, Chatenet-Duchene L, et al. Plasma lipoprotein distribution and lipid transfer activities in patients with type IIb hyperlipidemia treated with simvastatin. Atherosclerosis 1999; 143:415-425.
29. 29 Cheung MC, Wolfbauer G, Brown BG, Albers JJ. Relationship between plasma phospholipid transfer protein activity and HDL subclasses among patients with low HDL and cardiovascular disease. Atherosclerosis 1999; 142:201-205.
30. 30 Riemens SC, Van Tol A, Sluiter WJ, Dullaart RP. Acute and chronic effects of a 24-hour intravenous triglyceride emulsion challenge on plasma lecithin: cholesterol acyltransferase, phospholipid transfer protein, and cholesteryl ester transfer protein activities. J Lipid Res 1999; 40:1459-1466.
31. 31 Lagrost L, Mensink RP, Guyard-Dangremont V, Temme EH, Desrumaux C, Athias A, et al. Variations in serum cholesteryl ester transfer and phospholipid transfer activities in healthy women and men consuming diets enriched in lauric, palmitic or oleic acids. Atherosclerosis 1999; 142:395-402.
32. 32 Albers JJ, Pitman W, Wolfbauer G, Cheung MC, Kennedy H, Tu AY, et al. Relationship between phospholipid transfer protein activity and HDL level and size among inbred mouse strain., J Lipid Res 1999; 40:295-301.
33. 33 Zoppo A, Maggi F, Zanca R, Baggi L, Ruggio C, Catapano A. Gemfibrozil reduces phospholipid transfer protein activity during the postprandial phase. Abstracts on 'The 69th Scientific Sessions' Programs of the American Heart Association'. Circulation (supplement) 1996; 94: 1-276 [abstract 1603].
34. 34 Guo Z, Yuan C, Nishida H, Nishida T. Effects of nutritional and hormonal factors on phospholipid transfer protein (PLTP) secretion and gene expression in HepG2 cells. Abstracts on 'Experimental Biology 97'. [abstract 981] FASEB J 1997; 11: A169.
35. 35 Tu AY, Albers JJ. DNA sequences responsible for reduced promoter activity of human phospholipid transfer protein by fibrate. Biochem Biophys Res Commun 1999; 264:802-807.
36. 36 Tahvanainen E, Jauhiainen M, Funke H, Vartiainen E, Sundvall J, Ehnholm C. Serum phospholipid transfer protein activity and genetic variation of the PLTP gene. Atherosclerosis 1999; 146:107-115.
37. 37 Rye KA, Jauhiainen M, Barter PJ, Ehnholm C. Triglyceride-enrichment of high density lipoproteins enhances their remodelling by phospholipid transfer protein. J Lipid Res 1998; 39:613-622.
38. 38 Cheung MC, Wolfbauer G, Albers JJ. Plasma phospholipid mass transfer rate: relationship to plasma phospholipid and cholesteryl ester transfer activities and lipid parameters. Biochim Biophys Acta 1996; 1303:103-110.
39. 39 Desrumaux C, Athias A, Bessede G, Verges B, Farnier M, Persegol L, et al. Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol 1999; 19:266-275. This is the first description of PLTP mass determination in human plasma samples using a competitive ELISA method. A relation between PLTP mass levels and glucose metabolism is proposed.
40. 40 Huuskonen J, Ekström M, Tahvanainen E, Vainio A, Metso J, Pussinen P, et al. Quantification of human plasma phospholipid transfer protein (PLTP): relationship between PLTP mass and phospholipid transfer activity. Atherosclerosis 2000; 150. A sandwich-type ELISA method for the determination of PLTP mass is described. Correlation between the specific activity of PLTP and plasma triglyceride concentration in nonfasting plasma samples is demonstrated.
41. 41 Jauhiainen M, Huuskonen J, Baumann M, Metso J, Oka T, Egashira T, et al. Phospholipid transfer protein (PLTP) causes proteolytic cleavage of apolipoprotein A-I. J Lipid Res 1999; 40:654-664. A novel in-vitro function of PLTP, the cleavage of apolipoprotein A-I, is described.